Phytic Acid

Summary

Phytic Acid (CHEMBL1233511) is a phase-3 clinical-stage small-molecule iron chelator; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 660.04 Da · C6H18O24P6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1233511
Name	Phytic Acid
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	890
ChEBI	CHEBI:17401
Molecular formula	C6H18O24P6
Molecular weight	660.04
InChIKey	IMQLKJBTEOYOSI-UHFFFAOYSA-N

SMILES: C1(C(C(C(C(C1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O

IUPAC name: (2,3,4,5,6-pentaphosphonooxycyclohexyl) dihydrogen phosphate

ChEBI definition: A myo-inositol hexakisphosphate in which each hydroxy group of myo-inositol is monophosphorylated.

Pharmacological roles (ChEBI): iron chelator, antineoplastic agent, signalling molecule, cofactor.

Other ChEBI roles (chemical / environmental): Escherichia coli metabolite, mouse metabolite.

Also known as: Acide fytique, Acido fitico, Alkalovert, Dermofeel pa-3, E391, Exfoderm, Fytic acid, Inositol hexaphosphate, Inositol hexaphosphoric acid, Inositolhexaphosphoric acid, NSC-269896, Phytic acid

Parent form; salt/anhydrous children: CHEMBL2106435, CHEMBL3989600

Patent coverage: 48,605 distinct patent families (97,597 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Toxin B.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P18177	5.87	Kd	1360	nM	CHEMBL_ACT_26115870
P18177	5.08	EC50	8390	nM	CHEMBL_ACT_26115884

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03030703	Not specified	COMPLETED	Cystatin SN Binds to Phytic Acid and Predicts Non-heme Iron Bioavailability

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).